pharma · No medical condition. · Breast cancer
George Institute for
The George Institute
George Institute for clinical programs — 187 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Sydney, NSW 2042, AU
- Founded
- 1999
- Employees
- 841
- Programs
- 406
- Drugs
- 522
- Patents
- 0
George Institute for projects
187 ClinicalTrials.gov programs sponsored by George Institute for.
George Institute for has 187 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IJB-LBC-NEOCHECK2018
The George Institute
Luminal B Breast Cancer
1 trial -
IJB-REGINA-2020
The George Institute
Locally-advanced stage II-III rectal cancer
1 trial -
IJB-SYNERGY-012017
The George Institute
Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
1 trial -
IJB-ZEPHIR02-2024
The George Institute
advanced/metastatic HER2-positive breast carcinoma
1 trial -
IJB-ZEPHIR02-2024
The George Institute
advanced/metastatic HER2-positive breast carcinoma
1 trial -
IKF/AIO-ZANGEA
The George Institute
Gastroesophageal Adenocarcinoma
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
The George Institute
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
IMFINZI 50 mg/mL concentrate for solution for infusion.
The George Institute
unresectable stage III NSCLC (Non–small-cell lung cancer)
1 trial -
IMLIFIDASE
The George Institute
kidney trasplant
1 trial -
IMMUWHY
The George Institute
Advanced stage intrahepatic biliary tract cancer (BTC)
1 trial -
IMMUWIN
The George Institute
Intermediate stage hepatocellular carcinoma (HCC)
1 trial -
INDOCYANINE GREEN
The George Institute
Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery
1 trial -
IOR-IISML42037
The George Institute
Lung Cancer
1 trial -
IOR-REG-2501
The George Institute
Cutaneous Basal Cell Carcinoma
1 trial -
IPC 2022-067
The George Institute
acute myeloid leukemia
1 trial -
IPC 2024-001
The George Institute
acute myeloid leukemia
1 trial -
IRSP-PSI-2024-171
The George Institute
Major depressive disorder
1 trial -
IRSSP-001
The George Institute
Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.
1 trial -
ISA-HC-NK
The George Institute
Multiple myeloma
1 trial -
IVERMECTIN
The George Institute
Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.
1 trial -
Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
The George Institute
Ovarian Cancer
1 trial -
K-001-201
The George Institute
Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Liver Fibrosis
1 trial -
KETOROLAC, PREGABALIN
The George Institute
Estrogen receptor-positive early breast cancer (ER + BC).
1 trial -
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
The George Institute
Colon cancer
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion.
The George Institute
basal cell carcinoma
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion.
The George Institute
Cutaneous squamous cell carcinoma (ccSCC)
1 trial -
LUMYKRAS 120 mg film-coated tablets
The George Institute
locally-advanced and unresectable or metastatic NSCLC with KRAS G12C
1 trial -
Levact 2 for Relapsed/refractory large B-cel…
The George Institute
Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma
1 trial -
Lidocaína B. Braun /ml solución inyectable for headache pain related to SAH, S…
The George Institute
headache pain related to SAH, Spontaneous subarachnoid hemorrhage
1 trial -
Lonsurf / film-coated tablets for FGFR2b-positive, advanced or me…
The George Institute
FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction
1 trial -
Loratadina NORMON 10 mg Comprimidos EFG
The George Institute
Effect of loratadine in patients with lymphangioleiomyomatosis
1 trial -
MIA2019/CT/258
The George Institute
melanoma brain metastases
1 trial -
MIBIOTIMI
The George Institute
Breast cancer
1 trial -
Metformin Zentiva 500 mg Filmtabletten
The George Institute
Multidrug rezistant pulmonary tuberculosis
1 trial -
NADALS-001-ALS -2021
The George Institute
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
NeoART
The George Institute
HER2 positive resectable esophagogastric adenocarcinoma
1 trial -
NeoMatryx
The George Institute
Merkel Cell Carcinoma
1 trial -
OLAPARIB, BEVACIZUMAB
The George Institute
Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer
1 trial -
OMEPRAZOLE , ACETYLSALICYLIC ACID
The George Institute
Colorectal cancer
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion.
The George Institute
Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma
1 trial -
ORI2025-16
The George Institute
Colon cancer
1 trial -
OXY-APS
The George Institute
schizophrenia or other primary psychotic disorders (SSD)
1 trial -
Omomyc
The George Institute
Advanced High-Grade Osteosarcoma
1 trial -
Ozempic solution for Craving for and use of chemsex…
The George Institute
Craving for and use of chemsex-related drugs
1 trial -
PELICAN-IPC 2015-016
The George Institute
Breast cancer
1 trial -
PHERFLOT
The George Institute
HER2-positive, localized esophagogastric adenocarcinoma
1 trial -
PIROXICAM, LIDOCAINE HYDROCHLORIDE
The George Institute
lateral epicondylitis
1 trial -
PRAVASTATIN
The George Institute
Patients with severe and radio-induced breast fibrosis after breast cancer
1 trial
Frequently asked questions
How many clinical projects does George Institute for have?
187 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.